Business
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial Subjects who have completed the two-year follow-up in either SOL-1 or SOL-R have an opportunity to enroll in the SOL-X trial for an additional three years SOL-X is designed to build on AXPAXLI’s successful SOL-1 Phase 3 trial by exploring the potential to improve long-term visual outcomes with a dramatically reduced treatment burden BEDFORD, Mass., April 29,
About this update from Ocular Therapeutix, Inc.
[{"type":"image","alt":"Ocular Therapeutix, Inc.","displaySize":"","headline":null,"caption":"Ocular Therapeutix, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/67aba0a08455988daf68787482afba8f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/x8AZ3pCd8rX_NNStYxPmTQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MQ--/https://media.zenfs.com/en/globenewswire.com/67aba0a08455988daf68787482afba8f","width":300,"height":101}},"lazy":false},{"type":"text","content":"SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial ","length":139,"tagName":"p"},{"type":"text","content":"Subjects who have completed the two-year follow-up in either SOL-1 or SOL-R have an opportunity to enroll in the SOL-X trial for an additional three years","length":154,"tagName":"p"},{"type":"text","content":"SOL-X is designed to build on AXPAXLI’s successful SOL-1 Phase 3 trial by exploring the potential to improve long-term visual outcomes with a dramatically reduced treatment burden","length":179,"tagName":"p"},{"type":"text","content":"BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the first patient has been enrolled in the SOL-X long-term extension trial for AXPAXLI (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD).","length":389,"tagName":"p"},{"type":"text","content":"“The initiation of SOL-X reflects our continued outstanding execution and unwavering commitment to redefining the retina experience. Following the remarkable results from SOL-1, where AXPAXLI demonstrated unmatched durability and sustained disease control, SOL-X is designed to extend that story into the long-term outcomes that matter most to patients and retinal specialists,” said Pravin U. Dugel, MD, Executive Chairman, President and CEO of Ocular Therapeutix. “We believe continuous VEGF suppression with AXPAXLI has the potential not only to maintain vision, but to fundamentally alter the trajectory of disease by reducing the risk of fibrosis and atrophy associated with pulsatile therapies used to treat wet AMD today. By starting AXPAXL...